{"id":52292,"date":"2022-12-22T16:02:40","date_gmt":"2022-12-22T15:02:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-life-sciences-bpo-market-analysis-report-2022-a-827-5-billion-market-by-2030-focus-on-medical-devices-outsourcing-pharmaceutical-outsourcing-researchandmarkets-com\/"},"modified":"2022-12-22T16:02:40","modified_gmt":"2022-12-22T15:02:40","slug":"global-life-sciences-bpo-market-analysis-report-2022-a-827-5-billion-market-by-2030-focus-on-medical-devices-outsourcing-pharmaceutical-outsourcing-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-life-sciences-bpo-market-analysis-report-2022-a-827-5-billion-market-by-2030-focus-on-medical-devices-outsourcing-pharmaceutical-outsourcing-researchandmarkets-com\/","title":{"rendered":"Global Life Sciences BPO Market Analysis Report 2022: A $827.5 Billion Market by 2030 – Focus on Medical Devices Outsourcing, Pharmaceutical Outsourcing – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Life Sciences BPO Market Size, Share & Trends Analysis Report by Service (Medical Devices Outsourcing, Pharmaceutical Outsourcing), by Region (North America, APAC), and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global life sciences BPO market size is expected to reach USD 827.5 billion by 2030, registering a CAGR of 9.2% years.\n<\/p>\n

\nThe rising costs of drug development; pre-clinical and clinical trials; and post-marketing surveillance; a rise in the patent cliff; a growing product pipeline; and regulatory constraints are some of the major factors driving the market.\n<\/p>\n

\nThe pharmaceutical and biotech industries invest heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of drug development, such as drug discovery, pre-clinical studies, and clinical trials, require huge financial, technological, and human resources.\n<\/p>\n

\nTo cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth and profitability. Altogether, these trends are expected to boost the life sciences outsourcing market over the forecast period.\n<\/p>\n

\nDuring the COVID-19 pandemic, a significant number of outsourcing providers expanded their existing manufacturing and research facilities to meet the growing demand for COVID-19 vaccines and diagnostics. Even post-pandemic, CDMOs are practicing similar strategies to support the future demand for pharmaceuticals. For instance, in April 2022, Aenova Group developed a new facility for manufacturing highly potent drugs with an investment of EUR 10 million.\n<\/p>\n

\nThe adoption of such strategies by the market players is expected to be profitable for the market. There has been a rising demand to reduce the cost of manufacturing and development of drugs and medical devices. Outsourcing manufacturing, research, and marketing services provide pharmaceutical and medical device companies with cost- and time-saving benefits.\n<\/p>\n

\nThis is expected to have a positive impact on the market. Over the years, mergers and acquisition deals between CROs and CDMOs have increased. The rising demand for clinical services and the growing need for specialized service providers to improve the focus on their core competencies are some of the factors that are expected to drive the incidence of M&A deals.\n<\/p>\n

\nLife Sciences BPOMarket Report Highlights<\/strong>\n<\/p>\n